Using mobile health technology for breast cancer diagnosis in Nigeria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to train Nigerian radiologists in performing ultrasound-guided breast biopsies using mobile health devices. By implementing a practical training program, the researchers seek to enhance the skills of local healthcare providers in diagnosing breast cancer. The focus is on creating a sustainable model that integrates technology into clinical practice, thereby improving patient outcomes in low and middle-income countries. The study will involve the use of mHealth devices to facilitate this training and implementation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 and older female.
* Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy or surgical excision at the Nigerian hospital where the patient is seeking diagnosis.

Exclusion Criteria:

* Participants unwilling to sign consent.
* Participants under the age of 18.

Where it's running

• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting
• Lagos University Teaching Hospital
  Idi-Araba, Lagos, Nigeria Recruiting
• Federal Medical Centre Owo (Data Collection Only)
  Owo, Ondo State, Nigeria Recruiting
• University Of Nigeria Teaching Hospital (UNTH) Ituku-Ozalla Enugu
  Enugu, Nigeria Recruiting
• Obafemi Awolowo University Teaching Hospitals Complex (Data Collection Only)
  Ile-Ife, Nigeria Recruiting
• Olabisis Onabanjo University Teaching Hospital (Data Collection Only)
  Sagamu, Ogun State, Nigeria Active not recruiting

Study contacts

• Principal investigator: Eliabeth Sutton, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Elizabeth Sutton, MD
• Email: suttone@mskcc.org
• Phone: 646-888-5455

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• UCF MammoChat mammogram image repository for AI development

  This project collects donated mammogram images and questionnaire data from adults who had breast imaging to help build and test AI that could read mammograms more accurately.

  Recruiting University of Central Florida · Orlando, Florida · NCT07214883

• Elacestrant plus trastuzumab deruxtecan for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after CDK4/6 and endocrine therapy

  This trial tests whether combining elacestrant with trastuzumab deruxtecan helps people with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after CDK4/6 inhibitor and endocrine treatment.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07198724

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.